Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company announced that Lomecel B has been granted the Fast Track designation by the FDA, only a week after being granted the RMAT designation, which we believe further demonstrates the positive momentum of LGVN.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced that Lomecel B has been granted the Fast Track designation by the FDA, only a week after being granted the RMAT designation, which we believe further demonstrates the positive momentum of LGVN.

LGVN: Alzheimer's Drug on a Roll with FDA

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families.</li><li> Under new leadership, the company has focused on specific objectives, cut costs, and looked to maximize revenue opportunities.</li><li>We believe the company is on a better and more sustainable track and are excited about ongoing developments and the just released 1Q2024 earnings report reinforces that view.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under new leadership, the company has focused on specific objectives, cut costs, and looked to maximize revenue opportunities.We believe the company is on a better and more sustainable track and are excited about ongoing developments and the just released 1Q2024 earnings report reinforces that view.

LGVN: Focus and Cost Controls Improve Outlook

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families.</li><li> The company announced the completion of an encouraging meeting with investigators involved in the ongoing trial of Lomecel-B for the treatment of HLHS.</li><li>Additionally, the LGVN announced it has signed its first contract for the use of its state-of-the-art manufacturing facility.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. The company announced the completion of an encouraging meeting with investigators involved in the ongoing trial of Lomecel-B for the treatment of HLHS.Additionally, the LGVN announced it has signed its first contract for the use of its state-of-the-art manufacturing facility.

LGVN: Positive Trial Update and First Contract

United States

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

vTv Therapeutics Inc. operates as a clinical-stage pharmaceutical company. The Company focuses on the discovery and development of human therapeutics to fill unmet medical needs. vTv Therapeutics serves customers in the United States.

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company. The Company designs and develops proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. KALA BIO markets its products worldwide.

Evelo Biosciences, Inc. operates as a bio-technology company. The Company develops therapies for the treatment of the gut-body network. Evelo Biosciences also offers treatment for cancer and inflammatory diseases. Evelo Biosciences serves customers in the State of Massachusetts.

UNITY Biotechnology, Inc. operates as a biotechnology company. The Company develops therapeutics that prevents, halts, and reverses osteoarthritis, ophthalmology, and pulmonary diseases. UNITY Biotechnology serves the health care sectors in the United States.

Cortexyme, Inc. operates as a biotech company. The Company develops therapeutics and diagnostics for the treatment of alzheimer disease and other neurodegenerative disorders. Cortexyme serves clients in the State of California.

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Alaunos Therapeutics Inc. operates as a clinical stage cellular immuno-oncology company. The Company focuses on the treatment of solid tumors through adoptive TCR-T cell therapy. Alaunos Therapeutics serves customers worldwide.

Cynata Therapeutics Ltd is involved in regenerative medicine.  The Company is focused on the commercialization of a stem cell platform.

Biotron Limited specializes in the funding, management and commercialization of biomedical projects that result from research conducted at the John Curtin School of Medical Research, a research institute within the Australian National University.  The Group conducts diagnostic and therapeutic research with the intention of creating compounds and diagnostics that can be sold or licensed.

China Regenerative Medicine International Limited is engaged in research and development of bio-medical and healthcare products, and medical techniques, the provision of the production and sales of tissue engineering products and its related by-products, as well as sales and distribution of medical products and equipment.

Alterity Therapeutics Limited operates as a biotechnology company. The Company researches and develops therapeutic drugs used for treatment of alzheimer's diseases and age related disorders. Alterity Therapeutics serves patients in Australia.

Daesung Microbiological Labs Co., Ltd. develops and manufactures canine, poultry, swine, and bovine drugs and vaccines.  The Company's products have applications for increasing immunity and preventing epidemic for livestock. Daesung Microbiological Labs also researches microorganism for ocean and soil improvement purposes.

D.Western Therapeutics Institute Inc.(DWTI) is a biotechnology (bio-venture) company that focuses on development of new drugs. The Company's focus is on protein kinase inhibitors. DWTI discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.

D.Western Therapeutics Institute Inc. (4576 JP)

TRANS GENIC INC. develops, produces, and sells specific idiotype bearing antibody (bio reagent).  The Company also develops mutant mice and sells mice' genetic function analysis data.

Ribomic, Inc. develops ribonucleic acids (RNA) called aptamers. The company conduct research and develops new medication based on Ribomic Aptamer Refined Th erapeutics System. The company also conduct advisory to pharmaceutical companies and product licensing.

Prescient Therapeutics Limited is an oncology company. The Company researches, develop, and commercializes novel cancer treatments treatments. Prescient Therapeutics treats myeloma, breast, and pancreatic cancer.

Vectorite Biotech Inc. is a biomedical company focused on the research and development of adult healthy cells and cell formulation, medical technologies and product development of targeted immune cell therapy treatment to treat disease and improve the patients' quality of life.

Longeveron Inc. operates as a clinical stage biotechnology company. The Company focuses on developing cellular therapies for specific aging-related and life-threatening conditions. Longeveron serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Longeveron (LGVN US)

LGVN: Alzheimer's Drug on a Roll with FDA

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

LGVN: Alzheimer's Drug on a Roll with FDA

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

LGVN: Focus and Cost Controls Improve Outlook

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...

Zacks Small Cap Research

LGVN: Positive Trial Update and First Contract

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. The...

Zacks Small Cap Research

LGVN: Focus and Cost Controls Improve Outlook

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)